Ruxolitinib coronavirus clinical trial : Incyte revealed that it is working with the US Food and Drug Administration (FDA) to launch the phase 3 RUXCOVID clinical trial to assess the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients with COVID-19 associated cytokine storm syndrome. The ruxolitinib plus standard-of-care will be compared to […]
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as per the latest pharma acquisition news. As per the terms of the all-cash deal, Novartis will acquire The Medicines Company for $85.00 per share. The Medicines Company, which is headquartered […]
Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the US Food and Drug Administration (FDA) for its use in sickle cell disease. Formerly known as SEG101, Adakveo has been indicated to be used for bringing down the frequency of vaso-occlusive crises (VOCs), or pain crises, in patients, aged 16 […]
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu (brolucizumab) injection for wet age-related macular degeneration (AMD). Also called RTH258, Beovu is now the first FDA approved anti-VEGF which is said to deliver greater fluid resolution compared to aflibercept. […]
Novartis acquisition of IFM Tre : Novartis has signed a deal worth up to $1.575 billion to acquire US biopharma company IFM Tre from IFM Therapeutics. Novartis acquisition of IFM Tre The acquisition of the US biopharma company, which was only launched last year, is expected to add certain immunomodulatory drugs to the Swiss pharma […]
In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical giant Novartis to create Anthos Therapeutics, a new biopharma company focused on developing innovative therapies for high-risk cardiovascular patients. With an initial capital infusion of $250 million, Blackstone Life Sciences will oversee the development and operational control […]
Novartis has achieved a significant milestone with the FDA’s approval of Egaten (triclabendazole) for the treatment of fascioliasis in patients aged six years and older. This makes Egaten the only FDA-approved drug for treating the neglected tropical disease, which affects millions worldwide. Fascioliasis, caused by parasitic flatworms Fasciola hepatica and Fasciola gigantica, typically spreads through […]
Novartis has announced plans to acquire CellforCure, a French contract development and manufacturing organisation (CDMO), from LFB for an undisclosed amount. The deal underscores the Swiss pharmaceutical giant’s ambition to solidify its leadership in the cell and gene therapy market. Strategic acquisition of a key player The acquisition includes CellforCure’s manufacturing facility in Les Ulis […]
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for cancer treatment. The deal, first announced in October 2018, was finalised following shareholder approval earlier this week. A strategic move into radioligand and CAR-T therapies Endocyte specialises in developing radioligand […]